Hero Finding
Cost and value is the lowest-rated of 11 capabilities and the second-most-important factor buyers weigh.
Across 45 senior executives, therapeutic-area expertise led the capability benchmark at 84% Good or Excellent and was also the most-cited selection factor at 76%. Cost and value inverted that pattern: cited as a key factor by 71% of buyers, just behind therapeutic expertise, while only 36% rated the brand Good or Excellent on it and 56% rated it merely average. It is the only attribute in the study that sits in the top tier of importance and the bottom tier of perceived performance at the same time.
Share rating the brand Good or Excellent (%) · six of 11 capability dimensions shown · common base of 45
Key Findings
What the benchmark surfaced.
Six signals from the capability benchmark, the importance crossing, and the segment and role cuts, grounded in 45 senior-executive interviews.
The equity base is solid and drifting upward.
Across the 45 senior executives, 69% rated the brand excellent or very good overall, and 67% said they would definitely or probably shortlist it for a major new clinical program. The trajectory is a net-positive drift: 60% said their view had held about the same over the past two to three years, 28% said it had improved against 11% who said it had declined, and the improvement ran strongest among Large Pharma at 39%.
The brand is strongest exactly where buyers care most.
Therapeutic-area expertise was the top-rated capability at 84% Good or Excellent and the single most important factor buyers named when selecting a CRO, cited by 76%. Global reach and geographic capability ranked second on performance at 80% against 53% naming it a key factor: the brand over-delivers on it. On the attributes buyers weigh most, the brand delivers.
Cost and value is the only attribute in the top tier of importance and the bottom tier of performance.
Cost and value was the lowest-rated capability of the 11: only 36% rated it Good or Excellent, while 56% rated it merely average. That would be unremarkable except that cost and value was the second-most-important selection factor in the market, cited by 71% of buyers, just behind therapeutic expertise. The crossing, rather than any single low score, is the finding: the brand's weakest dimension is one the market cannot ignore.
Cost sensitivity concentrates where new biotech relationships are won.
81% of small and mid-size biopharma buyers named cost and value a key selection factor, significantly more than the 56% of Large Pharma who did, and those same smaller-company buyers rated the brand's cost and value the lowest. The pressure point is sharpest in the fastest-growing segment of the market, the one where new relationships are won.
Technology, data and AI is the second gap, and the market's forward priority.
Technology, data and AI was the second-lowest-rated capability at 51% Good or Excellent. Looking forward, speed, technology and cost were the three most-cited areas the brand most needs to improve, and when buyers were forced to name the single highest-impact fix, cost and value led at 22% with technology, data and AI second at 18%. The improvement agenda points at the same two gaps the capability benchmark exposed.
Perception splits by buying seat, and procurement is the strongest advocate.
The functions that run trial execution rated the brand highest: Clinical Operations and Procurement both averaged 4.0 of 5 on overall perception, Clinical Development sat at 3.7, and strategy- and regulatory-facing buyers rated it lowest at 3.2, a significant spread. Procurement was the most willing to shortlist the brand of any function, at 100%, with the remaining functions between 59 and 67%.
Our clinical trial budgets are getting more and more scrutinized for expenditures, and cost is probably the number one item that's currently being looked at as we are implementing all, yeah, all kinds of cost savings measures.
Clinical Operations Director · Large pharma
Study Design
N=45senior pharma and biotech executives
Large Pharma to emerging biotech
11-dimension capability benchmark and probed open ends in one instrument
The sample was built for seniority and decision authority: C-suite, EVP, SVP, VP and Director-level executives who personally evaluate, select or manage CRO partnerships, spanning five buyer functions from trial execution to procurement and regulatory. Fielding ran four days, 10 to 14 April 2026, with per-interview QC scoring reconciled across two independent expert networks and adaptive consistency checks between each scaled rating and its open-ended justification. Every score carried an AI-moderated follow-up asking why, branching separately on low and high ratings, so the benchmark arrived with a coded reason behind every number.
Sample by segment
Mix
What the guide covered
- Unaided brand impressions and spontaneous value-proposition articulation, captured before any prompted attribute list
- Selection-factor importance: which capabilities matter when evaluating a CRO, with AI-probed reasons on every choice
- 11-dimension capability rating matrix on a Good-to-Excellent scale, with follow-ups branching on low and high scores
- Perception trajectory over the past two to three years and what drove any shift
- Shortlist likelihood for a major new clinical program
- Improvement priorities: capped multi-select plus the single highest-impact fix
Who qualified
- C-suite, EVP, SVP, VP and Director-level executives at pharma and biotech organizations
- Personally evaluate, select or manage CRO partnerships
- Five buyer functions: Clinical Operations, Clinical Development, Medical Affairs, Procurement, Regulatory Affairs
- Two independent expert networks, reconciled per interview to a verified base of 45
Crosstab · Importance vs Performance
Where demand and perceived delivery cross.
Share naming each capability an important CRO selection factor against the share rating the brand Good or Excellent on it, on the common 45-respondent base. Cost and value is the only dimension near the top on importance and the bottom on performance. Highlighted row = the exposure.
| Named key factor | Rated Good or Excellent | |
|---|---|---|
| Therapeutic area expertise | 76% | 84% |
| Cost and value | 71% | 36% |
| Global reach and geographic capability | 53% | 80% |
| Technology, data and AI | 27% | 51% |
Common base of 45 · Small/mid biopharma 81% vs Large Pharma 56% on cost · significance-tested · Client and peer CROs blinded · Only attribute top-tier on importance, bottom-tier on performance
Voice of Customer
What CRO buyers actually said.
Verbatim excerpts from the AI-probed open ends, selected to span company scale, buyer function, and seniority across the 45-interview base.
“I guess I'd like the bigger CROs to understand that small biotech isn't big co, isn't big pharma. And, we we would like to dance with the bigger CROs, but we can't afford you. And I'm not sure you quite understand our our business.”
“It's just their pricing is on par with some of the bigger CROs, but not particularly attractive or competitive, so they're average.”
“We also have enough experience from previous CROs of who has all the change orders and who bids low. We have found that typically the CRO that bids lowest has the most change orders, and, we almost categorically reject the cheapest option.”
“We look at total cost of ownership. We're willing to pay more for best in class.”
“Therapeutic area expertise decreases onboarding time, drives strategic decision making in a partnership between the sponsor and the CRO, reduces timelines of training and execution deliverables. They have a playbook and understand competitive intelligence and what to expect from sites.”
“This is one of the most critical elements to reduce total cost of ownership and ensure scalability across our programs.”
Implications · what the evidence supports
Four readings from the research.
What brand and commercial leadership took into the corporate strategy work, grounded in the capability benchmark and the segment and role cuts.
The strengths the market weighs most are already the brand's highest-rated capabilities.
Therapeutic depth and global reach lead the capability benchmark at 84% and 80% Good or Excellent, and therapeutic expertise is also the most-cited selection factor at 76%. The strengths are real, defensible, and aligned to demand; the corporate story the data supports leads with them.
Cost and value is the single highest-leverage perception repair.
At 71% importance and 36% Good or Excellent, cost and value is the one dimension the market cannot ignore and the brand does not yet own, and it drags on shortlist consideration. The gap bites hardest in small and emerging biotech, where 81% name cost a key factor and ratings run lowest, the same segment where new relationships are won.
Technology, data and AI is both the second gap and the market's forward priority.
At 51% Good or Excellent, technology, data and AI is the second-lowest-rated capability, and it rises to second place at 18% when buyers name the single highest-impact fix, behind cost and value at 22%. The current benchmark and the forward improvement agenda point at the same two dimensions.
Perception splits by function, and procurement is already the internal advocate.
Clinical Operations and Procurement both average 4.0 of 5 on overall perception while strategy- and regulatory-facing buyers sit at 3.2, a significant spread, and procurement's willingness to shortlist, at 100%, tested significantly higher than other functions. The functions that run execution already advocate; the strategy and regulatory seats hold the most ground for the message to cover.
Signals the data flagged
- Cost and value moves off its 36% Good-or-Excellent floor on a follow-up wave
- The 56% merely-average middle on cost and value breaks toward the positive pole
- Small and emerging biotech ratings on cost close toward the Large Pharma read
- Technology, data and AI clears its 51% mid-tier read on the next benchmark
Risks the data surfaced
| Cost perception drags shortlist consideration where new biotech relationships are won | High |
| Technology and AI gap hardens as the market's forward priority | Med |
| Strategy- and regulatory-facing functions stay cooler than execution seats | Med |
| Single-wave baseline; the two-to-three-year trajectory is respondent-recalled | Low |